Using the TyG index to detect early microvascular blockage after emergency PCI for heart attack
Official title: Triglyceride Glucol Index for Predicting the Value of No-Reflow in Patients Undergoing Emergency PCI for Acute Myocardial Infarction
Run by The Third Xiangya Hospital of Central South University · NCT07042321 · Data updated 2026-11-12
This project will test whether the TyG (triglyceride-glucose) index can help doctors spot early small-vessel blockage (microvascular obstruction) in people treated with emergency PCI for a heart attack.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | The Third Xiangya Hospital of Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan Province,China) |
| Status | Recruiting |
| Started | June 1, 2024 |
| Main results expected | August 31, 2025 |
| Study ends | August 31, 2025 |
| Registry record updated | July 2, 2025 |
| Trial ID | NCT07042321 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) presenting with STEMI within guideline time windows or very high‑risk NSTEMI who undergo emergency PCI and can receive CMR 3–7 days after the procedure and provide informed consent.
✕Probably not a fit
Patients with non-obstructive MI, severe chronic kidney disease (eGFR <20 mL/min/1.73 m²), failed emergency PCI, pregnancy, or those unable to obtain clear CMR images are excluded and unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective cohort will enroll about 300 patients with acute myocardial infarction treated with emergency percutaneous coronary intervention at the Third Xiangya Hospital between June 2024 and August 2025. Participants will have cardiac magnetic resonance imaging 3–7 days after PCI and collection of demographic data, clinical history, coronary angiography findings, laboratory metabolic markers (including blood glucose and lipids), IVUS plaque characteristics, and CMR results. The cohort will be stratified by TyG index level to examine the relationship between TyG and presence of early microvascular obstruction and to compare in-hospital cardiovascular adverse events across TyG groups. Analyses will test associations between baseline TyG values and MVO on CMR while controlling for relevant confounders.
Why it matters
Potential benefit: If successful, the TyG index could provide a simple early marker to identify heart attack patients at higher risk of microvascular obstruction so clinicians can tailor monitoring and treatment.
How similar studies have gone: Prior observational work has linked the TyG index and other metabolic markers to cardiovascular risk, but applying TyG specifically for early detection of MVO after emergency PCI is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * STEMI symptom onset time \< 12 hours. * STEMI symptom onset time 12-48 hours, with ongoing ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias. * Very high-risk NSTEMI; undergoing emergency PCI treatment. * Voluntary signed informed consent form. Exclusion Criteria: * Non-obstructive acute myocardial infarction. * Severe chronic kidney disease (defined as estimated glomerular filtration rate \<20 mL/min per 1.73 m²). * Pregnant women or those planning to become pregnant. * Failure of emergency PCI. * Unclear CMR images
Where it's running
-
Xiangya Third Hospital of Central South University
Changsha, Hunan Province,China, China Recruiting
Study contacts
- Study coordinator: can Zhu Can
- Email: zhucan1021@163.com
- Phone: +8613348674820
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can 1-Hz rTMS help with heart rhythm and inflammation after a heart attack?
This trial tests whether daily 1-Hz repetitive transcranial magnetic stimulation can improve heart rate variability and reduce inflammation in people who have had an acute myocardial infarction, compared with a sham procedure.
-
Trends and risk factors for adverse events after primary PCI in AMI patients over 20 years
This study looks at real-world AMI patients who had a primary PCI to see how often serious events happen during a 2-year follow-up and what factors predict them.
-
SPIKE FLOW endocardial pacing lead safety and performance study
This study tests whether the SPIKE FLOW temporary endocardial pacing lead is safe and effective in adults needing temporary pacing during heart-related conditions.
-
Predict Arrhythmia Risk with Intelligent Software
Researchers are testing AI-powered predictions to see if clinicians can spot patients at risk for dangerous heart rhythms using bedside ECG data.
-
Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care
In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.
-
BRIDGE: Embedding consumer mHealth tools into cardiac rehab
This study tests whether adding a mobile health tool to standard center-based cardiac rehab helps heart patients stay active and follow healthy habits.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.